Back to News
Feb 26, 2026 4:10 PM

Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are trading lower Thursday afternoon after the lupus-focused drugmaker posted fourth quarter earnings and raised expectations for continued growth in 2026.

Here’s what investors need to know.

Aurinia Pharmaceuticals stock is feeling bearish pressure. What’s pressuring AUPH stock?

Lupkynis Sales Drive Full-Year Growth

The company reported fourth-quarter 2025 adjusted earnings of 26 cents a share, beating analysts' consensus of 22 cents and surging from one cent a year earlier. Quarterly revenue rose to $77.1 million from $59.9 million, topping the Street's $74.8 million forecast.

Sales of flagship lupus nephritis medicine Lupkynis increased 29% year over year to $74.2 million in the quarter and 25% for the full year, reaching $271.3 million. Total 2025 revenue climbed 20% to $283.1 million, while net ...